Fig. 1The effects of tunicamycin and thapsigargin on insulin mRNA expression in INS-1 cells. Northern blot analysis of insulin mRNA expression in INS-1 cells treated with tunicamycin (A) and thapsigargin (B). INS-1 cells were treated with tunicamycin (2 µg/mL) for 24 hours or thapsigargin (1 µM) for 5 hours. 18S rRNA levels were analyzed as an internal control. Data in bar graph are the mean ± SEM of three independent measurements. aP < 0.01 and bP < 0.001 compared to control.
Fig. 2The effects of tunicamycin and thapsigargin on TRB3 protein expression in INS-1 cells. Western blot analysis of TRB3 protein expression in the presence of tunicamycin (A) and thapsigargin (B). INS-1 cells were incubated with tunicamycin (2 µg/mL) and thapsigargin (1 µM) for indicated times. β-actin protein levels were analyzed as an internal control. The data in bar graph are the mean ± SEM of three independent measurements. aP < 0.01 and bP < 0.001 compared to 0 hour.
Fig. 3The effects of adenovirus-mediated overexpression of TRB3 on insulin, PDX-1 and MafA mRNA expression. Northern blot analysis of insulin, PDX-1 and MafA mRNA expression in INS-1 cells infected with adenovirus encoding TRB3 (Ad-TRB3). INS-1 cells were infected with the indicated doses of Ad-TRB3 or Ad-LacZ for 24 hours. 18S rRNA levels were analyzed as an internal control. Data in the bar graph are the mean ± SEM of three independent measurements. aP < 0.01 and bP < 0.001 compared to control.
Fig. 4The effects of TRB3 on insulin promoter activity. INS-1 cells were cotransfected with the human insulin promoter (200 ng/well) and the indicated amounts of an expression vector for TRB3 for 24 hours. Data represent the mean ± SEM of three independent measurements. aP < 0.01 and bP < 0.001 compared to control.